Proceeds will support advancement of an exosome therapy to treat a urea cycle disorder OXFORD, United Kingdom, 22 March 2019 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has secured £1.5 million in funding from Innovate UK, the UK’s Innovation Agency, through the Biomedical Catalyst Early … Read more
Highly experienced life sciences executive with a track record of overseeing strong company growth and value creation Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce the appointment of Dr Edwin Moses as Non-Executive Chairman. Edwin will bring a wealth of experience to Evox, as the Company continues … Read more
Evox Therapeutics to expand its work on cell-targeted delivery of nucleic acid-based drugs OXFORD, United Kingdom, 10 December 2018 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has secured an undisclosed amount of funding from the Bill & Melinda Gates Foundation. The funds will be used … Read more
Prestigious accolade recognises the potential impact of the Company’s disruptive exosome drug platform OXFORD, United Kingdom, 3 December 2018 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, was yesterday named in the list of The Sunday Times Fast Track Disruptors to Watch. Disruptors to Watch identifies ten of the most … Read more
OXFORD, United Kingdom, 13 November 2018 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has secured £655,000 in funding from Duchenne UK. The grant will be invested to support exploration of the Company’s exosome-based therapeutic platform to deliver either full-length dystrophin or its shorter variants in … Read more
Proceeds will advance transformative exosome therapeutics pipeline towards the clinic. Continued expansion of world-leading exosome platform for delivery of different drug modalities OXFORD, United Kingdom, 3 September 2018 Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, today announces that it has raised £35.5 million ($45.4 million) of new capital in … Read more
Expansion significantly increases laboratory space, creating new job opportunities in the area OXFORD, United Kingdom, 26 April 2018 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces that it has expanded into a new laboratory and office space at The Oxford Science Park, to enhance its research and development (R&D) … Read more